Choose ORACEA Capsules
for your papulopustular rosacea patients
A unique
formulation
Learn how this formulation of 30 mg immediate release and 10 mg delayed release beads, does not compromise on strength1–3
Superior GI tolerability
See how ORACEA Capsules showed superior gastrointestinal (GI) tolerability vs doxycycline 100 mg and did not induce symptoms of nausea, diarrhea, or vomiting2
Suitable for long-
term use†
Learn how you may limit the risk of antibiotic resistance with
ORACEA Capsules, a non-antibiotic dose that remained below the antimicrobial threshold in a long-term study6–10†
*30 mg immediate release and 10 mg delayed release beads
†No evidence of bacterial resistance in a 9-month clinical study10
Maintain
clearer skin
See the effectiveness of
ORACEA Capsules monotherapy in maintaining treatment success11‡
Resources tailored to
you
Here you’ll find up-to-date information, patient resources, and the latest rosacea insights
‡Treatment success was defined as achieving an IGA of clear or near clear, or achieving a minimum of a 2 grade IGA improvement11
Oracea capsules
When it’s right for the long term,§
write for rosacea
§No evidence of bacterial resistance in a 9-month clinical study10
Important Safety Information
Indication: ORACEA® (doxycycline) 40 mg* capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA does not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in subjects treated with ORACEA were nasopharyngitis, diarrhea, hypertension and sinusitis. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years) and may cause reversible inhibition of bone growth. If Clostridium difficile associated diarrhea (CDAD) occurs, may need to discontinue ORACEA. Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*30 mg immediate release and 10 mg delayed release beads
REFERENCES
1. ORACEA [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2014. 2. Del Rosso JQ, et al. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(8):573–576. 3. Bhatia N. ORACEA 40 mg Capsules for papulopustular rosacea. The Dermatologist. 2013;6(21s):1-4. Available at: https://www.hmpgloballearningnetwork.com/site/thederm/site/cathlab/event/oracea-40-mg-capsules-papulopustular-rosacea-1. Last accessed: September 2021. 4. Theobald K, et al. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6(5):221–226. 5. Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007;33(2):78–81. 6. Fowler JF. Anti-inflammatory dose doxycycline for the treatment of rosacea. Expert Rev Dermatol. 2007;2(5):523–531. 7. Baldwin HE. Diagnosis and treatment of rosacea: state of the art. J Drugs Dermatol. 2012;11(6):725–730. 8. Etchegaray JP, Wagner N, Shah MS, Difalco RJ, inventors; Galderma S.A., Cerovene, Inc. assignees. Doxycycline formulations, and methods of treating rosacea. US Patent 8,652,516 Bl. February 18, 2014. 9. Data on file. ORACEA PK Profile. Galderma Laboratories, L.P. 10. Preshaw PM, et al. Modified-release sub-antimicrobial dose doxycycline enhances scaling and root planning in subjects with periodontal disease. J Periodontol. 2008;79(3):440–452. 11. Data on File. GLI.04.SPR.US10183
